Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002238 · ClinicalTrials.gov registry record · Phase 3
Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00002238: Completed Phase 3 study, sponsored by Bayer.
NCT00002238 is a Phase 3 study that has completed, run by Bayer. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002238, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
To evaluate the safety and efficacy of interferon beta (Betaseron) in AIDS and advanced AIDS related complex (ARC) patients receiving a reduced-dose zidovudine (AZT) regimen.
Interventions
- DRUG Zidovudine
- DRUG Interferon beta-1b
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
What the finished NCT00002238 record still lists
NCT00002238 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which Zidovudine is the first listed.
NCT00002238 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002238 about?
NCT00002238 is a clinical study titled "Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen". To evaluate the safety and efficacy of interferon beta (Betaseron) in AIDS and advanced AIDS related complex (ARC) patients receiving a reduced-dose zidovudine (AZT) regimen.
What is the current status of trial NCT00002238?
This trial is currently completed. It is a Phase 3 study.
What interventions are being tested in trial NCT00002238?
The interventions under investigation include: Zidovudine (DRUG), Interferon beta-1b (DRUG).
Who is sponsoring clinical trial NCT00002238?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.